GlassScriptPhysician profile
Stewart A Robbins
NPI 1841367588
$1,572.43
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $88.41 · 2021: $11.40 · 2022: $108 · 2023: $776 · 2024: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $957.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.72 | 2019-2024 | Skyrizi, Linzess, Viberzi |
| Qol Medical, LLC | $254.42 | 2019-2020 | |
| Janssen Biotech, INC. | $207.99 | 2019-2023 | Remicade, Stelara, Simponi Aria |
| Pfizer INC. | $147.54 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $82.67 | 2023 | Idacio |
| Capsovision, INC. | $75.65 | 2023 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $71.69 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.54 | 2022-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $59.53 | 2019-2023 | Ocaliva |
| Celgene Corporation | $56.22 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $45.37 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $45.10 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $38.47 | 2023 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $35.87 | 2020-2022 | |
| Genzyme Corporation | $22.43 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $21.67 | 2023 | |
| Ardelyx, INC. | $21.61 | 2023 | Ibsrela |
| Evoke Pharma, INC. | $15.94 | 2023 | Gimoti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stewart Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.